Morphological evaluation of dysmyelopoiesis in decitabine-treated patients with myelodysplastic syndromes
- Authors: Dvirnyk VN1, Kokhno AV1, Glasko EN1, Gemdzhian ÉG1, Diagileva OA1, Platonova TL1, Parovichnikova EN1
-
Affiliations:
- Гематологический научный центр Минздрава России, Москва
- Issue: Vol 85, No 7 (2013)
- Pages: 65-71
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31311
- ID: 31311
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
V N Dvirnyk
Гематологический научный центр Минздрава России, Москва
Email: vdvirnyk@mail.ru
125167 Москва, Новый Зыковский пр-д, д. 4а
A V Kokhno
Гематологический научный центр Минздрава России, Москва
E N Glasko
Гематологический научный центр Минздрава России, Москва
É G Gemdzhian
Гематологический научный центр Минздрава России, Москва
O A Diagileva
Гематологический научный центр Минздрава России, Москва
T L Platonova
Гематологический научный центр Минздрава России, Москва
E N Parovichnikova
Гематологический научный центр Минздрава России, Москва
References
- van de Loosdrecht A.A., Vellenga E. Myelodysplasia and apoptosis: new insights into ineffective erythropoiesis. Med Oncol 2000; 17: 16-21.
- Bogdanovic A.D., Trpinac D.P., Jankovic G.M. et al. Incidence and role of apoptosis in myelodysplastic syndrome: morphological and ultrastructural assessment. Leukemia 1997; 11: 656-659.
- Raza A., Mundle S., Iftikhar A. et al. Simultaneous assessment of cell kinetics and programmed cell death in bone marrow biopsies of myelodysplastics reveals extensive apoptosis as the probable basis for ineffective hematopoiesis. Am J Hematol 1995; 48: 143-154.
- Parker J.E., Mufti Gh.J. The Myelodysplastic Syndromes: A Matter of Life or Death. Acta Haematologica 2004; 111: 78-99.
- Jaffe E.S, Harris N.L., Vardiman J.W. et al. World Heals Organisation Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC 2001.
- Swerdlov S.H., Campo E., Harris N.L. et al. World Heals Organisation Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC 2008.
- Cheson B.D. Bennett L.M. Kantarjian H et all. Report of international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-3674.
- Leone G., Teofili L., Voso M.T., Lybbert M. DNA methylation and demethylating drugs in myelodysplasting syndromes and secondary leukemias. Haematologica 2002; 87: 1324-134.
- Steensma D.P., Bennett J.M. The Myelodysplastic Syndromes Diagnosis and Treatment. Mayo Clin Proceed 2006; 81 (1): 104-130.
- Issa J.P., Garsia-Manero G., Giles F.J. et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2-deoxycytidine (decitabine) in hematopoetic malignancies. Blood 2004; 103 (5): 1635-1640.
- Wijermans P.W., Libbert M., Verhoef G. et al. Low-dose 5-aza-2-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in eidderly patients. J Clin Oncol 2000; 18: 956-962.
- Lubbert M., Susiu S., Baila L. et al. Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome ineligible for intensive chemotherapy: final results of the randomized phase III study of the European Organisathion for research and treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 2011; 15: 1987-1996.
- Кохно А.В., Паровичникова Е.Н. Терапия миелодисплазии гипометилирующими препаратами. В кн.: Савченко В.Г. (ред.). Программное лечение лейкозов. М: ГНЦ 2008: 318-327.
- Покровская О.С., Менделеева Л.П., Капланская И.Б. и др. Ангиогенез в костном мозге больных множественной миеломой на различных этапах высокодозной химиотерапии. Клин онкогематол 2010; 4: 347-353.
- Любимова Л.С., Савченко В.Г., Менделеева Л.П. и др. Трансплантация аллогенного костного мозга при хроническом миелолейкозе. Тер арх 2004; 7: 18-24.
- Менделеева Л.П., Савченко В.Г., Павлова О.А. и др. Высокодозная терапия и трансплантация аутологичных гемопоэтических клеток при лимфосаркомах. Современ онкол 2002; Экстра-выпуск: 12-13.
- Greenberg P., Cox C., LeBeau M. et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89: 2079-2088.
- Goasquen J.E., Bennett J.M. Classification and morphologic features of the myelodysplastic syndromes. Semin Oncol 1992; 19 (1): 4-13.
- Germing U., Gattermann N., Strupp C. et al. Validation of the WHO proposals for the classification of primary myelodysplastic syndromes. Leukemia Res 2000; 24: 983-992.
- Cheson B.D., Greenberg P.L., Bennett J.M. et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006: 108: 419-425.